Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00309985
Other study ID # E3805
Secondary ID E3805U10CA180794
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date September 26, 2006
Est. completion date July 2024

Study information

Verified date March 2024
Source Eastern Cooperative Oncology Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether androgen-ablation therapy is more effective with or without docetaxel in treating metastatic prostate cancer. PURPOSE: This randomized phase III trial is studying androgen-ablation therapy and chemotherapy to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.


Description:

OBJECTIVES: Primary - Evaluate the ability of early chemotherapy to improve overall survival of patients commencing androgen deprivation for metastatic prostate cancer. Secondary - Determine whether early chemotherapy can increase the time to clinical progression (radiographic or symptomatic deterioration due to disease) over hormonal therapy alone. - Determine whether early chemotherapy can increase the time to development of hormone-refractory disease over hormonal therapy alone. - Determine whether early chemotherapy can increase the time to serological progression over hormonal therapy alone. - Determine rates of biochemical response at 6 months and 12 months in the chemohormonal arm versus the hormonal therapy alone arm. - Determine the frequency of adverse events and the tolerability of chemotherapy combined with hormonal therapy versus hormonal therapy alone. - Determine whether the postulated clinically meaningful increase in disease control is associated with an alteration in overall quality of life using the Functional Assessment of Cancer Therapy-Prostate questionnaire. - Determine the ability of prostate-specific antigen (PSA) changes to be a surrogate for clinical benefit from therapy and overall survival. Tertiary - Determine whether there are proteins differentially translated from the genome in hormone-sensitive prostate cancer, prostate cancer that has responded to hormonal therapy, and hormone-refractory prostate cancer. - Determine the frequency of constitutive polymorphisms of enzymes involved in steroid metabolism and other carcinogenic processes. - Determine whether the amount and frequency of certain carcinogenic proteins in prostate cancer tissue such as C-X-C chemokine receptor type 4 (CXCR-4) and manganese superoxide dismutase can be correlated with a poor prognosis. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age (≥ 70 vs < 70), ECOG performance status (0-1 vs 2), combined androgen blockade for > 30 days (yes vs no), duration of prior adjuvant hormonal therapy (> 12 months vs ≤ 12 months), concurrent bisphosphonate use (yes vs no), and volume of disease (low vs high). Patients are randomized to 1 of 2 treatment arms. - Arm A (Androgen-Deprivation Therapy and Docetaxel): Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone [LHRH] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel intravenously (IV) over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. - Arm B (Androgen-Deprivation Therapy alone): Patients receive androgen-deprivation therapy (as in arm A) alone. Quality of life is assessed at baseline and at months 3, 6, 9 and 12. After completion of study treatment, patients are followed up periodically for up to 10 years.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 790
Est. completion date July 2024
Est. primary completion date December 23, 2013
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically confirmed prostate cancer - Metastatic disease - On androgen-deprivation therapy for < 120 days - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 - PS 2 eligible only if decline in PS is due to metastatic prostate cancer - Absolute neutrophil count = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Bilirubin = upper limit of normal (ULN) - Alanine aminotransferase (ALT) = 2.5 times ULN - Creatinine clearance = 30 mL/min - Prothrombin time (PT) and international normalized ratio (INR) = 1.5 times ULN (unless on therapeutic anticoagulation) - Partial thromboplastin time (PTT) = 1.5 times ULN (unless on therapeutic anticoagulation) - Fertile patients must use effective contraception - At least 4 weeks since prior major surgery and recovered from all toxicity prior to randomization - Prior adjuvant or neoadjuvant hormonal therapy allowed provided the following are true: - Therapy was discontinued = 12 months ago AND there is no evidence of disease, as defined by 1 of the following: - PSA < 0.1 ng/dL after prostatectomy plus hormonal therapy - PSA < 0.5 ng/dL and has not doubled above nadir after radiotherapy plus hormonal therapy - Therapy lasted no more than 24 months - Last depot injection must have expired by the 24-month mark - Prior palliative radiotherapy allowed if commenced within 30 days before starting androgen deprivation - Anti-androgen therapy allowed as single-agent therapy = 7 days before medial castration to prevent flare - More than 30 days (or 6 half-lives) (whichever is longer) since prior participation in another clinical trial - Concurrent participation in nontherapeutic trials allowed - Concurrent antiandrogen therapy (e.g., bicalutamide or flutamide) allowed, but not as sole hormonal therapy Exclusion Criteria: - Prostate-specific antigen (PSA) level has risen and met criteria for progression from its lowest point between the start of androgen-deprivation therapy and randomization - Prior malignancy in the past 5 years except for basal cell or squamous cell carcinoma of the skin - Other malignancies that are considered to have low potential to progress (e.g., grade 2, T1a transitional cell carcinoma) may be allowed if approved by study chair - Peripheral neuropathy > grade 1 - History of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 - Active cardiac disease, including the following: - Active angina - Symptomatic congestive heart failure - Myocardial infarction within the past 6 months - Prior chemotherapy in adjuvant or neoadjuvant setting - Prior hormone therapy in the metastatic setting - Concurrent 5-alpha reductase inhibitors - Simultaneous enrollment on Cancer and Leukemia Group B (CALGB) 90202

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
androgen-deprivation therapy
LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.
docetaxel
Given IV

Locations

Country Name City State
United States Summa Center for Cancer Care at Akron City Hospital Akron Ohio
United States Providence Cancer Center Anchorage Alaska
United States CCOP - Michigan Cancer Research Consortium Ann Arbor Michigan
United States Saint Joseph Mercy Cancer Center Ann Arbor Michigan
United States University of Michigan Comprehensive Cancer Center Ann Arbor Michigan
United States DeCesaris Cancer Institute at Anne Arundel Medical Center Annapolis Maryland
United States Langlade Memorial Hospital Antigo Wisconsin
United States Rush-Copley Cancer Care Center Aurora Illinois
United States University of Colorado Cancer Center at UC Health Sciences Center Aurora Colorado
United States Greater Baltimore Medical Center Cancer Center Baltimore Maryland
United States Greenebaum Cancer Center at University of Maryland Medical Center Baltimore Maryland
United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland
United States St. Agnes Hospital Cancer Center Baltimore Maryland
United States Veterans Affairs Medical Center - Baltimore Baltimore Maryland
United States Barberton Citizens Hospital Barberton Ohio
United States Mary Bird Perkins Cancer Center - Baton Rouge Baton Rouge Louisiana
United States Cleveland Clinic Beachwood Family Health and Surgery Center Beachwood Ohio
United States MeritCare Bemidji Bemidji Minnesota
United States Alta Bates Summit Comprehensive Cancer Center Berkeley California
United States Billings Clinic - Downtown Billings Montana
United States CCOP - Montana Cancer Consortium Billings Montana
United States Hematology-Oncology Centers of the Northern Rockies - Billings Billings Montana
United States St. Vincent Healthcare Cancer Care Services Billings Montana
United States Medcenter One Hospital Cancer Care Center Bismarck North Dakota
United States Mid Dakota Clinic, PC Bismarck North Dakota
United States St. Alexius Medical Center Cancer Center Bismarck North Dakota
United States Illinois CancerCare - Bloomington Bloomington Illinois
United States Mountain States Tumor Institute at St. Luke's Regional Medical Center Boise Idaho
United States Central Care Cancer Center at Carrie J. Babb Cancer Center Bolivar Missouri
United States Boston University Cancer Research Center Boston Massachusetts
United States Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute Boston Massachusetts
United States Bozeman Deaconess Cancer Center Bozeman Montana
United States St. Joseph's Medical Center Brainerd Minnesota
United States Skaggs Cancer Center at Skaggs Regional Medical Center Branson Missouri
United States Kings County Hospital Center Brooklyn New York
United States SUNY Downstate Medical Center Brooklyn New York
United States Bryn Mawr Hospital Bryn Mawr Pennsylvania
United States Roswell Park Cancer Institute Buffalo New York
United States Peninsula Medical Center Burlingame California
United States Lahey Clinic Medical Center - Burlington Burlington Massachusetts
United States Fairview Ridges Hospital Burnsville Minnesota
United States St. James Healthcare Cancer Care Butte Montana
United States Aultman Cancer Center at Aultman Hospital Canton Ohio
United States Graham Hospital Canton Illinois
United States Illinois CancerCare - Canton Canton Illinois
United States Saint Francis Medical Center Cape Girardeau Missouri
United States Illinois CancerCare - Carthage Carthage Illinois
United States Memorial Hospital Carthage Illinois
United States Rocky Mountain Oncology Casper Wyoming
United States West Virginia University Health Sciences Center - Charleston Charleston West Virginia
United States University of Virginia Cancer Center Charlottesville Virginia
United States Hematology and Oncology Associates Chicago Illinois
United States Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago Illinois
United States Adena Regional Medical Center Chillicothe Ohio
United States Marshfield Clinic - Chippewa Center Chippewa Falls Wisconsin
United States Case Comprehensive Cancer Center Cleveland Ohio
United States Cleveland Clinic Cancer Center at Fairview Hospital Cleveland Ohio
United States Cleveland Clinic Taussig Cancer Center Cleveland Ohio
United States MetroHealth Cancer Care Center at MetroHealth Medical Center Cleveland Ohio
United States Medical Oncology and Hematology Associates - West Des Moines Clive Iowa
United States CCOP - Columbus Columbus Ohio
United States Doctors Hospital at Ohio Health Columbus Ohio
United States Grant Medical Center Cancer Care Columbus Ohio
United States Mount Carmel Health - West Hospital Columbus Ohio
United States Riverside Methodist Hospital Cancer Care Columbus Ohio
United States Zangmeister Center Columbus Ohio
United States Mercy and Unity Cancer Center at Mercy Hospital Coon Rapids Minnesota
United States Geisinger Cancer Institute at Geisinger Health Danville Pennsylvania
United States Oakwood Cancer Center at Oakwood Hospital and Medical Center Dearborn Michigan
United States Decatur Memorial Hospital Cancer Care Institute Decatur Illinois
United States Grady Memorial Hospital Delaware Ohio
United States Veterans Affairs Medical Center - Denver Denver Colorado
United States CCOP - Iowa Oncology Research Association Des Moines Iowa
United States John Stoddard Cancer Center at Iowa Lutheran Hospital Des Moines Iowa
United States John Stoddard Cancer Center at Iowa Methodist Medical Center Des Moines Iowa
United States Medical Oncology and Hematology Associates at John Stoddard Cancer Center Des Moines Iowa
United States Medical Oncology and Hematology Associates at Mercy Cancer Center Des Moines Iowa
United States Mercy Cancer Center at Mercy Medical Center - Des Moines Des Moines Iowa
United States Delaware County Regional Cancer Center at Delaware County Memorial Hospital Drexel Hill Pennsylvania
United States CCOP - Duluth Duluth Minnesota
United States Duluth Clinic Cancer Center - Duluth Duluth Minnesota
United States Miller - Dwan Medical Center Duluth Minnesota
United States Veterans Affairs Medical Center - East Orange East Orange New Jersey
United States Marshfield Clinic Cancer Care at Regional Cancer Center Eau Claire Wisconsin
United States Fairview Southdale Hospital Edina Minnesota
United States Shaw Regional Cancer Center Edwards Colorado
United States Elkhart Clinic, LLC Elkhart Indiana
United States Elkhart General Hospital Elkhart Indiana
United States Michiana Hematology-Oncology, PC - Elkhart Elkhart Indiana
United States Green Bay Oncology, Limited - Escanaba Escanaba Michigan
United States Eureka Community Hospital Eureka Illinois
United States Illinois CancerCare - Eureka Eureka Illinois
United States Evanston Hospital Evanston Illinois
United States St. Francis Hospital Evanston Illinois
United States Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital Fairbanks Alaska
United States CCOP - MeritCare Hospital Fargo North Dakota
United States MeritCare Broadway Fargo North Dakota
United States Roger Maris Cancer Center at MeritCare Hospital Fargo North Dakota
United States Hunterdon Regional Cancer Center at Hunterdon Medical Center Flemington New Jersey
United States Genesys Hurley Cancer Institute Flint Michigan
United States Hurley Medical Center Flint Michigan
United States Front Range Cancer Specialists Fort Collins Colorado
United States Poudre Valley Hospital Fort Collins Colorado
United States Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital Fort Lauderdale Florida
United States Hembree Mercy Cancer Center at St. Edward Mercy Medical Center Fort Smith Arkansas
United States Fort Wayne Medical Oncology and Hematology Fort Wayne Indiana
United States Mercy and Unity Cancer Center at Unity Hospital Fridley Minnesota
United States Saint Luke's Mountain States Tumor Institute - Fruitland Fruitland Idaho
United States Northeast Georgia Medical Center Gainesville Georgia
United States University of Florida Shands Cancer Center Gainesville Florida
United States Galesburg Clinic, PC Galesburg Illinois
United States Illinois CancerCare - Cottage Galesburg Illinois
United States Adams Cancer Center Gettysburg Pennsylvania
United States Wayne Memorial Hospital, Incorporated Goldsboro North Carolina
United States Genesys Regional Medical Center Grand Blanc Michigan
United States St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center Grand Junction Colorado
United States Big Sky Oncology Great Falls Montana
United States Great Falls Clinic - Main Facility Great Falls Montana
United States Sletten Cancer Institute at Benefis Healthcare Great Falls Montana
United States Green Bay Oncology, Limited at St. Mary's Hospital Green Bay Wisconsin
United States Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center Green Bay Wisconsin
United States St. Mary's Hospital Medical Center - Green Bay Green Bay Wisconsin
United States St. Vincent Hospital Regional Cancer Center Green Bay Wisconsin
United States Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center Green Bay Wisconsin
United States California Cancer Care, Incorporated - Greenbrae Greenbrae California
United States Van Elslander Cancer Center at St. John Hospital and Medical Center Grosse Pointe Woods Michigan
United States Cancer Institute of New Jersey at Hamilton Hamilton New Jersey
United States Cherry Tree Cancer Center Hanover Pennsylvania
United States Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center Hartford Connecticut
United States Illinois CancerCare - Havana Havana Illinois
United States Hays Medical Center Hays Kansas
United States Geisinger Hazleton Cancer Center Hazleton Pennsylvania
United States St. Peter's Hospital Helena Montana
United States Pardee Memorial Hospital Hendersonville North Carolina
United States Kellogg Cancer Care Center Highland Park Illinois
United States Veterans Affairs Medical Center - Hines Hines Illinois
United States Hinsdale Hematology Oncology Associates Hinsdale Illinois
United States Hutchinson Area Health Care Hutchinson Minnesota
United States Hutchinson Hospital Corporation Hutchinson Kansas
United States Cleveland Clinic Cancer Center Independence Ohio
United States Indiana University Melvin and Bren Simon Cancer Center Indianapolis Indiana
United States Veterans Affairs Medical Center - Indianapolis Indianapolis Indiana
United States William N. Wishard Memorial Hospital Indianapolis Indiana
United States Veterans Affairs Medical Center - Iowa City Iowa City Iowa
United States Dickinson County Healthcare System Iron Mountain Michigan
United States Foote Memorial Hospital Jackson Michigan
United States University of Mississippi Cancer Clinic Jackson Mississippi
United States Mayo Clinic - Jacksonville Jacksonville Florida
United States UW Cancer Center Johnson Creek Johnson Creek Wisconsin
United States Joliet Oncology-Hematology Associates, Limited - West Joliet Illinois
United States Ella Milbank Foshay Cancer Center at Jupiter Medical Center Jupiter Florida
United States Borgess Medical Center Kalamazoo Michigan
United States Bronson Methodist Hospital Kalamazoo Michigan
United States West Michigan Cancer Center Kalamazoo Michigan
United States Glacier Oncology, PLLC Kalispell Montana
United States Kalispell Medical Oncology at KRMC Kalispell Montana
United States Kalispell Regional Medical Center Kalispell Montana
United States Provena St. Mary's Regional Cancer Center - Kankakee Kankakee Illinois
United States Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center Kansas City Kansas
United States Truman Medical Center - Hospital Hill Kansas City Missouri
United States Illinois CancerCare - Kewanee Clinic Kewanee Illinois
United States Kinston Medical Specialists Kinston North Carolina
United States Cascade Cancer Center at Evergreen Hospital Medical Center Kirkland Washington
United States Howard Community Hospital Kokomo Indiana
United States Gundersen Lutheran Center for Cancer and Blood La Crosse Wisconsin
United States La Grange Memorial Hospital La Grange Illinois
United States Center for Cancer Therapy at LaPorte Hospital and Health Services La Porte Indiana
United States Fairfield Medical Center Lancaster Ohio
United States Sparrow Regional Cancer Center Lansing Michigan
United States CCOP - Nevada Cancer Research Foundation Las Vegas Nevada
United States Nevada Cancer Institute Las Vegas Nevada
United States Lucille P. Markey Cancer Center at University of Kentucky Lexington Kentucky
United States North Shore Oncology and Hematology Associates, Limited - Libertyville Libertyville Illinois
United States St. Rita's Medical Center Lima Ohio
United States Arkansas Cancer Research Center at University of Arkansas for Medical Sciences Little Rock Arkansas
United States St. Mary Mercy Hospital Livonia Michigan
United States USC/Norris Comprehensive Cancer Center and Hospital Los Angeles California
United States Lynchburg Hematology-Oncology Clinic Lynchburg Virginia
United States Illinois CancerCare - Macomb Macomb Illinois
United States McDonough District Hospital Macomb Illinois
United States Dean Medical Center - Madison Madison Wisconsin
United States University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison Wisconsin
United States Holy Family Memorial Medical Center Cancer Care Center Manitowoc Wisconsin
United States HealthEast Cancer Care at St. John's Hospital Maplewood Minnesota
United States Minnesota Oncology - Maplewood Maplewood Minnesota
United States Strecker Cancer Center at Marietta Memorial Hospital Marietta Ohio
United States Bay Area Cancer Care Center at Bay Area Medical Center Marinette Wisconsin
United States Vince Lombardi Cancer Clinic - Marinette Marinette Wisconsin
United States Marshfield Clinic - Marshfield Center Marshfield Wisconsin
United States Saint Joseph's Hospital Marshfield Wisconsin
United States Tibotec Therapeutics - Division of Ortho Biotech Products, LP Marysville California
United States Mather Veteran Affairs Medical Center Mather California
United States Hillcrest Cancer Center at Hillcrest Hospital Mayfield Heights Ohio
United States Cardinal Bernardin Cancer Center at Loyola University Medical Center Maywood Illinois
United States Mercy Cancer Center at Mercy Medical Center Merced California
United States Idaho Urologic Institute, PA Meridian Idaho
United States Mountain States Tumor Institute - Meridian Meridian Idaho
United States CCOP - Mount Sinai Medical Center Miami Beach Florida
United States Saint Anthony Memorial Health Centers Michigan City Indiana
United States Tucker Center for Cancer Care at Orange Regional Medical Center Middletown New York
United States Medical College of Wisconsin Cancer Center Milwaukee Wisconsin
United States Hennepin County Medical Center - Minneapolis Minneapolis Minnesota
United States Virginia Piper Cancer Institute at Abbott - Northwestern Hospital Minneapolis Minnesota
United States Marshfield Clinic - Lakeland Center Minocqua Wisconsin
United States Michiana Hematology-Oncology, PC - South Bend Mishawaka Indiana
United States Saint Joseph Regional Medical Center Mishawaka Indiana
United States Montana Cancer Center at St. Patrick Hospital and Health Sciences Center Missoula Montana
United States Montana Cancer Specialists at Montana Cancer Center Missoula Montana
United States Memorial Medical Center Modesto California
United States Illinois CancerCare - Monmouth Monmouth Illinois
United States Montrose Memorial Hospital Cancer Center Montrose Colorado
United States Carol G. Simon Cancer Center at Morristown Memorial Hospital Morristown New Jersey
United States Good Samaritan Regional Health Center Mount Vernon Illinois
United States Knox Community Hospital Mount Vernon Ohio
United States Saint Luke's Mountain States Tumor Institute Nampa Idaho
United States Hematology Oncology Consultants - Naperville Naperville Illinois
United States MBCCOP - Meharry Medical College - Nashville Nashville Tennessee
United States Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick New Jersey
United States Yale Cancer Center New Haven Connecticut
United States MBCCOP - LSU Health Sciences Center New Orleans Louisiana
United States Medical Center of Louisiana - New Orleans New Orleans Louisiana
United States New Ulm Medical Center New Ulm Minnesota
United States NYU Cancer Institute at New York University Medical Center New York New York
United States Licking Memorial Cancer Care Program at Licking Memorial Hospital Newark Ohio
United States Newton-Wellesley Hospital Newton Massachusetts
United States Cancer Care and Hematology Specialists of Chicagoland - Niles Niles Illinois
United States BroMenn Regional Medical Center Normal Illinois
United States Community Cancer Center Normal Illinois
United States Illinois CancerCare - Community Cancer Center Normal Illinois
United States Mid-Illinois Hematology-Oncology Associates at Community Cancer Center Normal Illinois
United States Sutter Health - Western Division Cancer Research Group Novato California
United States Green Bay Oncology, Limited - Oconto Falls Oconto Falls Wisconsin
United States Oklahoma University Cancer Institute Oklahoma City Oklahoma
United States Community Hospital of Ottawa Ottawa Illinois
United States Oncology Hematology Associates of Central Illinois, PC - Ottawa Ottawa Illinois
United States McCreery Cancer Center at Ottumwa Regional Ottumwa Iowa
United States Cancer Center of Paoli Memorial Hospital Paoli Pennsylvania
United States Parma Community General Hospital Parma Ohio
United States Regional Cancer Center at Singing River Hospital Pascagoula Mississippi
United States Cancer Treatment Center at Pekin Hospital Pekin Illinois
United States Illinois CancerCare - Pekin Pekin Illinois
United States CCOP - Illinois Oncology Research Association Peoria Illinois
United States Methodist Medical Center of Illinois Peoria Illinois
United States Oncology Hematology Associates of Central Illinois, PC - Peoria Peoria Illinois
United States Proctor Hospital Peoria Illinois
United States Illinois CancerCare - Peru Peru Illinois
United States Illinois Valley Community Hospital Peru Illinois
United States Fox Chase Cancer Center - Philadelphia Philadelphia Pennsylvania
United States Kimmel Cancer Center at Thomas Jefferson University - Philadelphia Philadelphia Pennsylvania
United States Mayo Clinic Hospital Phoenix Arizona
United States Mount Carmel Regional Cancer Center Pittsburg Kansas
United States Jordan Hospital Club Cancer Center Plymouth Massachusetts
United States Michiana Hematology Oncology PC - Plymouth Plymouth Indiana
United States St. Joseph Mercy Oakland Pontiac Michigan
United States Mercy Regional Cancer Center at Mercy Hospital Port Huron Michigan
United States Southern Ohio Medical Center Cancer Center Portsmouth Ohio
United States Illinois CancerCare - Princeton Princeton Illinois
United States Commonwealth Hematology-Oncology, PC - Quincy Quincy Massachusetts
United States McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center Reading Pennsylvania
United States St. Joseph Medical Center Reading Pennsylvania
United States Ministry Medical Group at Saint Mary's Hospital Rhinelander Wisconsin
United States Marshfield Clinic - Indianhead Center Rice Lake Wisconsin
United States Humphrey Cancer Center at North Memorial Outpatient Center Robbinsdale Minnesota
United States Mayo Clinic Cancer Center Rochester Minnesota
United States University of California Davis Cancer Center Sacramento California
United States Seton Cancer Institute at Saint Mary's - Saginaw Saginaw Michigan
United States CentraCare Clinic - River Campus Saint Cloud Minnesota
United States Coborn Cancer Center Saint Cloud Minnesota
United States Saint Helena Hospital Saint Helena California
United States Lakeland Regional Cancer Care Center - St. Joseph Saint Joseph Michigan
United States Lakeside Cancer Specialists, PLLC Saint Joseph Michigan
United States CCOP - St. Louis-Cape Girardeau Saint Louis Missouri
United States David C. Pratt Cancer Center at St. John's Mercy Saint Louis Missouri
United States Midwest Hematology Oncology Group, Incorporated Saint Louis Missouri
United States Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis Saint Louis Missouri
United States CCOP - Metro-Minnesota Saint Louis Park Minnesota
United States Park Nicollet Cancer Center Saint Louis Park Minnesota
United States Regions Hospital Cancer Care Center Saint Paul Minnesota
United States United Hospital Saint Paul Minnesota
United States Cancer Therapy and Research Center San Antonio Texas
United States University Hospital - San Antonio San Antonio Texas
United States University of Texas Health Science Center at San Antonio San Antonio Texas
United States Veterans Affairs Medical Center - San Antonio (Murphy) San Antonio Texas
United States California Pacific Medical Center - California Campus San Francisco California
United States North Coast Cancer Care, Incorporated Sandusky Ohio
United States Sutter Pacific Medical Foundation Santa Rosa California
United States Mayo Clinic Scottsdale Scottsdale Arizona
United States CCOP - Virginia Mason Research Center Seattle Washington
United States Pacific Medical Center Seattle Washington
United States Virginia Mason Medical Center Seattle Washington
United States St. Francis Cancer Center at St. Francis Medical Center Shakopee Minnesota
United States St. Nicholas Hospital Sheboygan Wisconsin
United States Vince Lombardi Cancer Clinic - Sheboygan Sheboygan Wisconsin
United States Mercy Medical Center - Sioux City Sioux City Iowa
United States Siouxland Hematology-Oncology Associates, LLP Sioux City Iowa
United States St. Luke's Regional Medical Center Sioux City Iowa
United States Avera Cancer Institute Sioux Falls South Dakota
United States Hematology Oncology Associates - Skokie Skokie Illinois
United States CCOP - Northern Indiana CR Consortium South Bend Indiana
United States Memorial Hospital of South Bend South Bend Indiana
United States Frederick R. and Betty M. Smith Cancer Treatment Center Sparta New Jersey
United States Illinois CancerCare - Spring Valley Spring Valley Illinois
United States CCOP - Cancer Research for the Ozarks Springfield Missouri
United States Community Hospital of Springfield and Clark County Springfield Ohio
United States Hulston Cancer Center at Cox Medical Center South Springfield Missouri
United States Regional Cancer Center at Memorial Medical Center Springfield Illinois
United States St. John's Regional Health Center Springfield Missouri
United States Geisinger Medical Group - Scenery Park State College Pennsylvania
United States Marshfield Clinic at Saint Michael's Hospital Stevens Point Wisconsin
United States Saint Michael's Hospital Cancer Center Stevens Point Wisconsin
United States Lakeview Hospital Stillwater Minnesota
United States Cleveland Clinic Foundation - Strongsville Strongsville Ohio
United States Green Bay Oncology, Limited - Sturgeon Bay Sturgeon Bay Wisconsin
United States Aurora Medical Center Summit Wisconsin
United States Overlook Hospital Summit New Jersey
United States SUNY Upstate Medical University Hospital Syracuse New York
United States St. Francis Comprehensive Cancer Center Topeka Kansas
United States Tahoe Forest Cancer Center Truckee California
United States Mountain States Tumor Institute at St. Luke's Twin Falls Idaho
United States Vince Lombardi Cancer Clinic - Two Rivers Two Rivers Wisconsin
United States CCOP - Carle Cancer Center Urbana Illinois
United States Sutter Solano Medical Center Vallejo California
United States Ridgeview Medical Center Waconia Minnesota
United States St. John Macomb Hospital Warren Michigan
United States George Washington University Medical Center Washington District of Columbia
United States Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington District of Columbia
United States Marshfield Clinic - Wausau Center Wausau Wisconsin
United States University of Wisconcin Cancer Center at Aspirus Wausau Hospital Wausau Wisconsin
United States Oncology Alliance, SC - Milwaukee - West Wauwatosa Wisconsin
United States Mount Carmel St. Ann's Cancer Center Westerville Ohio
United States Diagnostic and Treatment Center Weston Wisconsin
United States Marshfield Clinic - Weston Center Weston Wisconsin
United States Michiana Hematology Oncology PC - La Porte Westville Indiana
United States Dickstein Cancer Treatment Center at White Plains Hospital Center White Plains New York
United States Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center Wilkes-Barre Pennsylvania
United States Willmar Cancer Center at Rice Memorial Hospital Willmar Minnesota
United States Marshfield Clinic - Wisconsin Rapids Center Wisconsin Rapids Wisconsin
United States Minnesota Oncology - Woodbury Woodbury Minnesota
United States Cleveland Clinic - Wooster Wooster Ohio
United States CCOP - Main Line Health Wynnewood Pennsylvania
United States Lankenau Cancer Center at Lankenau Hospital Wynnewood Pennsylvania
United States York Cancer Center at Apple Hill Medical Center York Pennsylvania
United States Genesis - Good Samaritan Hospital Zanesville Ohio

Sponsors (2)

Lead Sponsor Collaborator
ECOG-ACRIN Cancer Research Group National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival Overall survival is defined as the time from randomization to death or date last known alive. Survival data reflects the database as of December 23, 2013. Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry; then annually if patient is 5 - 10 years from study entry
Secondary Time to Clinical Progression Time to clinical progression is defined as the time from randomization to clinical progression. Clinical progression is defined as increasing symptomatic bone metastases, progression per Response Evaluation Criteria In Solid Tumors (RECIST) criteria or clinical deterioration due to cancer per investigator's opinion. Patients without documented clinical progression were censored at the date of last disease assessment. Secondary endpoint data reflect the database as of December 23, 2014. Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry; then annually if patient is 5 - 10 years from study entry
Secondary Time to Castration Resistant Prostate Cancer (Hormone Refractory Disease) Time to castration resistant prostate cancer is defined as the time from randomization to PSA progression or clinical progression, whichever occurred first. Patients without documented progression were censored at the date of last disease assessment. Secondary endpoint data reflect the database as of December 23, 2014. Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry; then annually if patient is 5 - 10 years from study entry
Secondary Proportion of Patients With PSA Complete Response (CR) at 6 Months PSA CR is defined as a PSA level less than 0.2 ng/ml measured for 2 consecutive measurements at least 4 weeks apart. Patients who met the criterion of PSA CR and had PSA level less than 0.2 ng/ml before and after the 6-month time point are considered as having a PSA CR at 6 months. Assessed at 6 months
Secondary Proportion of Patients With PSA Complete Response (CR) at 12 Months PSA CR is defined as a PSA level less than 0.2 ng/ml measured for 2 consecutive measurements at least 4 weeks apart. Patients who met the criterion of PSA CR and had PSA level less than 0.2 ng/ml before and after the 12-month time point are considered as having a PSA CR at 12 months. Assessed at 12 months
Secondary QOL Change From Baseline to 3 Months The primary QOL change was evaluated by the Functional Assessment of Cancer Therapy - Prostate (FACT-P) instrument. FACT-P is a self-report measure of both general and disease-specific QOL. Higher scores represent better QOL. The FACT-P (version 4) contains 39 likert items distributed over 5 subscales: physical (7 items), social/family (7 items), emotional (6 items), and functional (7 items) well-being, and the additional concerns related to prostate cancer scale (12 items). The FACT-P total score is calculated by summing all these 5 subscales and ranges from 0 to 156. Assessed at baseline and 3 months
See also
  Status Clinical Trial Phase
Completed NCT05381311 - Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
Completed NCT03532217 - Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer Phase 1
Not yet recruiting NCT06334120 - An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
Active, not recruiting NCT05059236 - A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. Phase 2
Completed NCT02799602 - Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer Phase 3
Not yet recruiting NCT06134271 - Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer Phase 2
Active, not recruiting NCT04934722 - Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension Phase 3
Recruiting NCT05901649 - A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
Withdrawn NCT03343977 - Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Phase 1/Phase 2
Active, not recruiting NCT04191096 - Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) Phase 3
Active, not recruiting NCT03879122 - A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer Phase 2/Phase 3